№ lp_1_2_45806
File format: docx Character count: 5760 File size: 100 KB
Clinical guidance outlining evidence-based considerations and stepwise dose reduction schedules for gabapentin and pregabalin in adults with persistent neuropathic pain, including safety risks and regulatory context.
Year: 2021
Language: English
Medical field: Pain management
Therapeutic class: Gabapentinoids
Medications covered: Gabapentin; Pregabalin
Indications discussed: Neuropathic pain
Patient population: Adults with persistent pain
Document type: Clinical guidance
Related guidance: Analgesic Tapering Guidelines for adult patients with persistent pain taking strong opioids and/or gabapentinoids
Regulatory references: NICE; MHRA
Dosage information: Included
Tapering schedules: Included
Risk considerations: Adverse effects; withdrawal effects; opioid co-prescribing risks
Geographic context: United Kingdom
Evidence sources: Cochrane Reviews; NICE guidance; Summary of Product Characteristics
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
The Co-Analgesic Efficacy of Preoperative Single Dose Gabapentin after Surgical Removal of Lower Third Molars
Year: 2021
Region / City: Żory, Poland
Topic: Pain Management, Dental Surgery
Document Type: Research Article
Institution: Medical University of Silesia in Katowice
Authors: Hanna Frelich-Truchel, Rafał Wiench, Piotr Wichary, Henryk Frelich, Hanna Misiołek
Target Audience: Medical professionals, dental surgeons, anesthesiologists
Period of validity: N/A
Date of Approval: 2021
Date of Changes: N/A
Pregabalin CR Submission for Neuropathic Pain Treatment in Adults
Year: 2021
Region / City: Australia
Topic: Neuropathic pain, Pregabalin CR, Pharmaceutical Submission
Document Type: Submission for Pharmaceutical Listing
Organization: Upjohn Australia Pty Ltd
Author: Not specified
Target Audience: Medical Practitioners, Pharmaceutical Regulators
Action Period: Not specified
Approval Date: 10 March 2021
Modification Date: Not specified
Clinical Criteria: Condition must be refractory to other treatments
PBS Indication: Neuropathic pain in adults
Treatment Phase: Initial and continuing
Prescriber: Medical Practitioners, Nurse Practitioners for continuing therapy
Source: Therapeutic Goods Administration (TGA)
Background: Pregabalin CR tablets were registered in Australia in March 2021 for neuropathic pain in adults.
Purpose of Submission: Request for listing pregabalin CR on the PBS for neuropathic pain treatment under the same clinical criteria as pregabalin IR
International Registration Status: Approved in the USA (2017) and Republic of Korea (2018) for neuropathic pain treatment
Requested Listing: Pregabalin CR tablets for inclusion in PBS under a General Schedule (GE)
Gabapentinoid Prescribing for Chronic Pain in Primary CareResources for Clinicians and BoardsVERSION 1.2 – 11th December 2018
Year: 2018
Region / City: Scotland
Topic: Chronic pain management, gabapentinoids prescribing
Document type: Guideline
Organization / Institution: Scottish Government
Author: Heather Harrison, Jason Cormack
Target audience: Clinicians, healthcare professionals, Boards
Period of validity: Ongoing
Approval date: 11th December 2018
Date of revisions: Not specified
NHS Shropshire, Telford and Wrekin Guidance: Gabapentinoid Prescribing in Chronic Pain
Year: 2018–2021
Region: Shropshire, Telford and Wrekin
Subject: Gabapentinoid prescribing in chronic pain
Document Type: Clinical prescribing guidance
Issuing Body: NHS Shropshire, Telford and Wrekin
Medicines Covered: Gabapentin; Pregabalin
Legal Framework: Misuse of Drugs Regulations 2001; Misuse of Drugs Act 1971
Clinical Scope: Chronic pain management
Key Topics: Misuse potential; Co-prescribing with opioids; Legal status; Off-label use; Risk management; Dose reduction; Cross-tapering; Renal function
Intended Audience: Prescribers and healthcare professionals
Appendices: Prescribing agreement; Example dose reduction; Example cross-taper; Direct switch guidance
Status: Schedule 3 Controlled Drugs (from 1 April 2019)
Topics: gabapentin pregabalin Gabapentinoid